Features of postinfarction remodeling in able-bodied patients

Objective. To evaluate postinfarction remodeling (PR) according to О myocardial Infarction (О-Mi) location within 1 year in able-bodied men during combination therapy including thrombolysis and maximum doses of statins. Subjects and methods. A follow-up was performed in 106 men under 60 years of age with primary Q-Mi, who were randomized Into 2 groups: 1)55 patients who took rosuvastatin 40 mg/day as part of drug therapy: 2)51 patients received atorvastatln 80 mg/day as part of drug therapy. According to age, the patients were divided Into subgroups: A) 49 (46.23%) young patients aged 30-44 years; B) 57 (53.77%) patients aged 45 to 60years. A control group consisted of 30 apparently healthy people without cardiovascular diseases. Results. The patients with Q-MI who took rosuvastatin for 1 year achieved more pronounced reductions In low-density lipoprotein (LDL) and C-reactive protein (CRP) levels compared to those who received atorvastatln. In the subgroup of young patients, the anterior location of Ml prevailed In 79.6%; In the subgroup of patients aged 45-60years, the lo wer location of Ml was In 64.9%. In both subgroups, the patients with anterior Q-MI showed an Increase In the left ventricle (LV) end-systollc diameter (ESD) during both early and late PR; In those with lower Q-MI, the Increased LV ESD was observed In persons aged 30-44 years during late PR. Conclusion. It is preferable to prescribe rosuvastatin 40 mg/day as part of combination therapy for able-bodied patients with the anterior location of Q-MI, by taking into account the characteristics of PR, as it contributes to a faster achievement of the target level of both LDL and CRP, which is one of the criteria for predicting the severity of Q-MI. One-year administration of the maximum doses of statins has been shown to be safe.